Fulcrum’s Pociredir Shows Strong HbF Induction in Sickle Cell Trial

Event summary

  • Fulcrum’s pociredir increased mean absolute fetal hemoglobin (HbF) by 12.2% in 12 weeks in the 20 mg dose cohort of the Phase 1b PIONEER trial.
  • 58% of patients achieved HbF levels ≥20%, with improvements in hemolysis markers and a 1.1 g/dL increase in total hemoglobin.
  • Pociredir was well-tolerated with no treatment-related serious adverse events reported.
  • Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026.

The big picture

Fulcrum’s positive Phase 1b data for pociredir in sickle cell disease positions the company to advance into later-stage trials, addressing a high unmet need in a genetically defined rare disease. The robust HbF induction and improvements in hemolysis markers suggest potential for a best-in-class therapy, though regulatory and competitive dynamics will shape its path to market.

What we're watching

Regulatory Pathway
Whether the FDA and EMA will provide favorable feedback on the design of the next trial, enabling a registration-enabling study in 2H 2026.
Clinical Efficacy
The durability of HbF induction and associated clinical benefits beyond the 12-week treatment period.
Competitive Positioning
How pociredir’s profile compares to other HbF inducers in development for sickle cell disease.